Lateralization in $^{11}$C-Metomidate PET and outcome of adrenalectomy in primary aldosteronism

Juhani Isojärvi\textsuperscript{1} | Marianna Viukari\textsuperscript{1} | Ilkka Pörsti\textsuperscript{2,3} | Helena Leijon\textsuperscript{4} | Tiina Vesterinen\textsuperscript{4} | Marko Seppänen\textsuperscript{5,6} | Pasi I. Nevalainen\textsuperscript{3} | Niina Matikainen\textsuperscript{1} 

\textsuperscript{1}Endocrinology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
\textsuperscript{2}Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
\textsuperscript{3}Department of Internal Medicine, Tampere University Hospital, Tampere, Finland
\textsuperscript{4}Department of Pathology, University of Helsinki and HUSLAB, Helsinki University Hospital, Helsinki, Finland
\textsuperscript{5}Turku PET Centre, University of Turku, Turku, Finland
\textsuperscript{6}Department of clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland

Correspondence
Niina Matikainen, Endocrinology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Email: niina.matikainen@hus.fi

Funding information
Helsinki University Hospital, Grant/ Award Number: TYH2020402 and VTR TYH2018111

Abstract
Introduction: Subtype classification method is essential when considering adrenalectomy as a possible treatment for primary aldosteronism. We aimed to retrospectively evaluate surgical outcomes of primary aldosteronism in patients who had undergone $^{11}$C-metomidate positron emission tomography ($^{11}$C-MTO-PET) for subtype classification.

Methods: Postoperative clinical and biochemical cure and histopathological diagnosis from biobank samples were retrospectively evaluated in 44 patients who had all undergone preoperative $^{11}$C-MTO-PET with or without adrenal venous sampling (AVS). We compared those operated based on $^{11}$C-MTO-PET alone and those with concordant or discordant lateralization in $^{11}$C-MTO-PET and AVS studies according to postoperative immunohistochemical findings and biochemical and clinical cure.

Results: Adrenalectomy side was based on $^{11}$C-MTO-PET alone in 14 cases and on AVS in 30 cases of whom 42 achieved complete and two partial biochemical cures. Among those who underwent AVS and were operated according to it, the two lateralization methods were concordant in 22 cases and discordant in 8 cases. Similar immunohistochemical profiles and cure rates were seen after $^{11}$C-MTO-PET alone or AVS-based operations. Respectively, those with concordant or discordant $^{11}$C-MTO-PET and AVS lateralization did not differ in surgical outcome. Together, we found errors of lateralization diagnostics with $^{11}$C-MTO-PET in 18% and with AVS in 3% among those eligible for adrenal surgery.

Conclusions: Outcomes of adrenalectomy based on clinically significant lateralization in $^{11}$C-MTO-PET alone correspond to those based on $^{11}$C-MTO-PET with concordant AVS lateralization. However, our results suggest that diagnosis of unilateral PA should be performed with caution with $^{11}$C-MTO-PET in case of discordant lateralization studies.
INTRODUCTION

Primary aldosteronism (PA), the most common cause of secondary hypertension, increases the risk of mortality and cardiovascular and cerebrovascular complications compared to essential hypertension.1–5 The risk of adverse outcomes can be reduced by mineralocorticoid receptor antagonists or even more with adrenalectomy in case of lateralization of aldosterone secretion.6–9

Recent meta-analysis and a prospective cohort study favour surgical treatment over mineralocorticoid receptor antagonists to reduce cardiovascular events and mortality in unilateral PA,9,10 but rigorous subtype classification is essential when considering adrenalectomy as a possible treatment. Anatomical imaging with adrenal computed tomography or magnetic resonance imaging has not proven sufficient sensitivity or specificity in most cases but may guide the treatment in young patients with clear PA, hypokalaemia and a solitary nodule.11–14 However, adrenal venous sampling (AVS), the gold standard method for lateralization diagnosis, poses methodological challenges.11,15,16 Previous reports suggested that functional imaging with [11C]metomidate positron emission tomography ([11C-MTO-PET) offers an alternative to AVS for PA subtype classification,17–19 but in our recent prospective study,20 [11C-MTO-PET was inferior to AVS.

In this study, we retrospectively analysed 44 adrenalectomized patients. Patients were eligible if they had undergone preoperative [11C-MTO-PET imaging, and adrenal biobank samples were available. Our aim was to evaluate in a retrospective cohort the power of [11C-MTO-PET as a diagnostic method for PA subtype classification according to the surgical outcome of postoperative immunohistochemical analysis and biochemical and clinical cure.

MATERIALS AND METHODS

Study population

The present analysis is a part of our project, which aims to elucidate the pitfalls of surgical treatment for primary hyperaldosteronism by means of adrenalectomy samples from Finnish biobanks. We retrospectively identified all subjects with a diagnosis of primary hyperaldosteronism (E26.0) who had an adrenalectomy sample available in the Finnish biobanks during 1.1.2000–31.12.2019 and had undergone preoperative [11C-MTO-PET imaging. Thirty-four of the subjects fulfilling the inclusion criteria were included in our previous study, which compared lateralization diagnostics between [11C-MTO-PET imaging and AVS in both operated and medically treated patients.20 Patient registry and biobank permissions were obtained, and the study was approved by the Ethics Committee of Helsinki University Hospital. We collected clinical and biochemical data from hospital records.

Lateralization studies

All [11C-MTO-PET studies were performed in Turku PET Centre without dexamethasone pretreatment, as previously described in detail.20,21 All scans were analysed by an expert in nuclear medicine, but the SUVs were inaccessible through biobank data. ACTH-stimulated AVS was performed at Tampere University Hospital for 36 subjects, 31 of which were successful. The cut points recommended by The Endocrine Society were applied for selectivity and lateralization indexes.12 Treatment decisions of subjects were based on clinical judgement in each case.

Histopathological methods

Haematoxylin and eosin-stained adrenal slides from biobanks were reviewed centrally at the Helsinki University Hospital by a single pathologist with special expertise in adrenal pathology. Immunohistochemical labelling was performed with a previously described primary antibody, CYP11B2 (aldosterone synthase, dilution 1:3000).22 Each sample was categorized as aldosterone-producing adenoma (APA) or non-APA based on immunohistochemistry as previously described.20,23,24

Evaluation of surgical outcome

Biochemical and clinical outcomes for each subject were determined according to the Primary Aldosteronism Surgical Outcome (PASO) criteria.25

Statistical analysis

Statistical analysis was performed using IBM SPSS Statistics version 27.0 (IBM Corp., Armonk, NY, USA). Shapiro–Wilks test was applied to test data distribution. Differences between the two subgroups were examined using independent samples t-test and Mann–Whitney U-test. p values <.05 were considered significant.
RESULTS

We identified 44 adrenalectomy specimens in the biobank database from subjects who fulfilled preoperative biochemical criteria for PA and had undergone preoperative \(^{11}\)C-MTO-PET imaging with or without AVS (Figure 1). Of the subjects, 14 were operated based on \(^{11}\)C-MTO-PET alone. The adrenalectomy side was based on AVS lateralization in 30 cases, 22 with concordant and eight with discordant lateralization in \(^{11}\)C-MTO-PET and AVS studies. Thus, a total of 36 subjects had concordant adrenalectomy and \(^{11}\)C-MTO-PET metabolic activity side, while eight had discordant \(^{11}\)C-MTO-PET metabolic activity and adrenalectomy side (Table 1 and Figure 1). Those who were operated based on \(^{11}\)C-MTO-PET either had or did not have anatomic nodule(s) in adrenal CT. Of these, 5 subjects had an unsuccessful AVS, eight had no preoperative AVS, while one subject showed no detectable lateralization in AVS.

Two subgroups were determined retrospectively: those with concordant adrenalectomy and \(^{11}\)C-MTO-PET metabolic activity side (Figure 1, grey background), and those with discordant \(^{11}\)C-MTO-PET and adrenalectomy side, for example bilateral, contralateral or normal \(^{11}\)C-MTO-PET metabolic activity (Figure 1, white background and Table 2). We compared these two subgroups according to their biochemical and clinical outcomes following the PASO criteria as well as postoperative histopathological diagnosis. Table 1 displays the baseline characteristics for all subjects and subgroups with concordant and discordant PET outcomes. Age did not significantly affect the outcome (data not shown).

The discordant group had significantly higher plasma renin activity and plasma sodium concentration and lower aldosterone-renin ratio (ARR) at baseline. Postoperatively, no statistical differences in systolic BP, diastolic BP, use of antihypertensive medication, plasma aldosterone concentration, plasma renin concentration or activity, ARR or plasma potassium concentration were found between these two groups (Table 1).

CYP11B2-based histopathological diagnosis and the outcome according to the PASO criteria for clinical and biochemical cure are presented in the Figure 1. Each subject exhibited either APA or non-APA as the final diagnosis, and the distribution between these histopathological diagnoses did not significantly differ: 67% vs. 33% for concordant and 50% vs. 50% for discordant groups, respectively \((p = .434)\). No statistical differences in the cure rates between the groups were detected (Table 1 and Figure 1). One subject was classified as having false negative AVS while after...
### TABLE 1: Patient characteristics

|                        | All subjects baseline | All subjects follow-up | Concordant group baseline | Concordant group follow-up | Discordant group baseline | Discordant group follow-up | p-value concordant vs discordant group baseline | p-value concordant vs discordant group follow-up |
|------------------------|-----------------------|------------------------|---------------------------|---------------------------|---------------------------|-----------------------------|--------------------------------------------|--------------------------------------------|
| Number (male/female)   | 44 (30/14)            | -                      | 36 (24/12)                | -                         | 8 (6/2)                   | -                           | -                                          | -                                          |
| Age (years)            | 56.0 (47.0–61.8)      | -                      | 56.0 (48.5–62.0)          | -                         | 54.0 (41.0–60.0)          | -                           | 0.501                                      | -                                          |
| BMI (kg/m²)            | 29.5 ± 5.2            | -                      | 28.8 ± 5.0                | -                         | 32.7 ± 5.1                | -                           | 0.050                                      | -                                          |
| Systolic BP (mmHg)     | 154 ± 18              | 133 ± 13               | 156 ± 19                  | 132 ± 14                  | 148 ± 12                  | 135 ± 9                     | 0.169                                      | 0.577                                      |
| Diastolic BP (mmHg)    | 93 ± 11               | 80 ± 9                 | 94 ± 12                   | 80 ± 10                   | 90 ± 6                    | 83 ± 6                      | 0.355                                      | 0.222                                      |
| Duration of treated hypertension (years) | 18.0 (13.0–29.0) | - | 17.0 (12.0–26.0) | - | 20.0 (16.5–30.5) | - | 0.211 | - |
| Antihypertensive medication (DDD) | 4.0 (2.0–5.3) | 2.0 (0.0–3.9) | 4.0 (2.0–5.6) | 1.5 (0.0–4.0) | 4.3 (3.6–4.9) | 2.3 (1.3–2.9) | 0.780 | 0.777 |
| Plasma aldosterone (pmol/l) | 765 (530-1226) | 82 (30-208) | 806 (543-1414) | 87 (30-208) | 612 (396-1164) | 56 (30-200) | 0.314 | 0.508 |
| PRA (μg/l/h)           | 0.7 (0.2–2.8)         | 0.2 (0.2–2.8)          | 0.6 (0.2–2.8)             | 0.4 (0.2–3.9)             | 0.9                       | 0.047                                      | 1.000                                      |
| ARR, PRA               | 3360 (1983-5575)      | 118 (17-503)           | 3690 (2665-7350)          | 140 (17-693)              | 1364 (1001-2451)          | 82                          | <0.001                                    | 0.738                                      |
| DRC (mU/l)             | 2.8 (1.7-5.2)         | 10.2 (5.3-19.5)        | 2.8 (1.7-5.2)             | 10.4 (5.6-21.2)           | -                        | 7.1                         | -                                         | 0.521                                      |
| ARR, DRC               | 338 (93-516)          | 12 (6-20)              | 338 (93-516)              | 13 (6-21)                 | -                        | 12                          | -                                         | 0.536                                      |
| Plasma potassium (mmol/l) | 2.8 ±0.4             | 4.0 ±0.5               | 2.9 ±0.4                  | 4.0 ±0.5                  | 2.8 ±0.2                 | 4.0 ±0.4                   | 0.386                                      | 0.932                                      |
| Plasma sodium (mmol/l) | 142.5 ± 2.5           | 140.3 ± 2.1            | 142.1 ± 2.4               | 140.3 ± 2.2               | 144.4 ± 2.7              | 140.3 ± 1.6                | 0.018                                      | 0.895                                      |
| Clinical cure complete/partial/absent, n (%) | - | 11/27/5 (26/63/12) | - | 10/21/4 (29/60/11) | - | 1/6/1 (13/75/13) | - | 0.702 |
| Biochemical cure complete/partial/absent, n (%) | - | 42/2/0 (95/5/0) | - | 34/2/0 (94/6/0) | - | 8/0/0 (100/0/0) | - | 1.000 |

Note: Data are number, mean ± standard deviation or median (interquartile range). Follow-up biochemical data were evaluated within a timeframe of a few days to 6 months after adrenalectomy and clinical data at a follow-up visit after intensification of the medical therapy. The subjects were divided into those with concordant and discordant $^{11}$C-MTO-PET metabolic activity side with respect to the adrenalectomy side.

Abbreviations: ARR, aldosterone-to-renin ratio; BMI, body mass index; BP, blood pressure; DDD, defined daily dose; DRC, direct renin concentration; PRA, plasma renin activity. Bold highlights p-values that are considered statistically significant.

a At baseline, renin was measured as PRA in 37 subjects and as DRC in 7 subjects. At follow-up, renin was measured as PRA in 18 subjects and as DRC in 16 subjects; 10 subjects had no renin measurements at follow-up, and their biochemical outcome was based on plasma potassium concentrations.

b Clinical cure was not evaluated for one subject in the concordant group.


| Subject | Sex | Age (years) | Duration of HT (years) | Operation side | Lateralization index | Histopathology | Biochemical cure | Clinical cure | 11C-MTO-PET lateralization | Metabolic activity side |
|---------|-----|-------------|-----------------------|----------------|---------------------|----------------|-----------------|---------------|--------------------------|----------------------|
| 1       | M   | 39          | 24                    | Right          | Non-lateralization | APA            | Absent          | Partial       | Complete biochemical cure | Contralateral        |
| 2       | M   | 60          | 15                    | Right          | No lateralization  | APA            | Complete        | Complete       | Complete biochemical cure | Contralateral        |
| 3       | M   | 53          | 18                    | Right          | No lateralization  | APA            | Absent          | Partial       | Complete biochemical cure | Contralateral        |
| 4       | M   | 60          | 16                    | Left           | No lateralization  | APA            | Complete        | Complete       | Complete biochemical cure | Contralateral        |
| 5       | M   | 55          | 16                    | Left           | No lateralization  | APA            | Partial         | Complete       | Complete biochemical cure | Contralateral        |
| 6       | M   | 67          | 18                    | Left           | No lateralization  | APA            | Complete        | Complete       | Complete biochemical cure | Contralateral        |
| 7       | F   | 47          | 18                    | Right          | No lateralization  | APA            | Complete        | Complete       | Complete biochemical cure | Bilateral            |
| 8       | F   | 47          | 18                    | Right          | No lateralization  | APA            | Complete        | Complete       | Complete biochemical cure | Bilateral            |

Note: Follow-up biochemical data were evaluated within a timeframe of a few days to 6 months after adrenalectomy and clinical data at a follow-up visit after intensification of the medical therapy. ARR, aldosterone-to-renin ratio; 11C-MTO-PET lateralization and presented with complete biochemical cure but absent clinical cure. Detailed data for those who underwent AVS-guided adrenalectomy but showed discordant 11C-MTO-PET lateralization are shown in Table 2. All these subjects had lateralization index clearly above the cut point of 4 and complete biochemical cure.

## 4 | DISCUSSION

The present series is the first report of surgical outcome after adrenalectomy in subjects with discordant metabolic activity side in preoperative functional imaging with 11C-MTO-PET. Our main findings are as follows: First, those operated based on 11C-MTO-PET alone or on concordant AVS and 11C-MTO-PET lateralization were not different regarding adrenalectomy outcome. This suggests that clinically relevant lateralization can be detected in 11C-MTO-PET. Secondly, AVS-guided adrenalectomy results in similar cure rates of primary aldosteronism in those with concordant and discordant 11C-MTO-PET metabolic activity findings. This suggests that diagnosis of unilateral PA should be performed with caution with 11C-MTO-PET in discordant cases.

In our study, biochemical and clinical cure rates in those with discordant operation and metabolic activity sides were quite good, with 88% demonstrating complete or partial clinical cure, and all subjects demonstrating complete biochemical cure. These results suggest corresponding surgical outcome than among those with concordant operation and metabolic activity side. However, the small number of subjects in the discordant group limits the conclusions. Furthermore, the diagnosis of APA was made in 50% of the cases in the discordant group, indicating that substantial number of the subjects had non-classic unilateral PA. A recent multicenter study reported increased incidence of cortical hyperplasia in patients without APA who did not achieve cure after adrenalectomy.26 Findings of aldosterone-producing micronodules were also common in our series (data not shown) and may partly explain bilateral or contralateral metabolic activity in 11C-MTO-PET. However, as shown in Table 2, four cases of APA were found among the eight with discrepancy between AVS and 11C-MTO-PET but with complete biochemical cure.

Even though the group with 11C-MTO-PET alone had corresponding outcomes to those with AVS-guided adrenalectomy, in our whole patient series, reliance on 11C-MTO-PET would have resulted in unnecessary refraining from surgery in 13.6% of the subjects, and additionally, the non-culprit adrenal gland would have been operated on in 4.5% of the patients. One subject with non-lateralizing AVS underwent adrenalectomy based on 11C-MTO-PET lateralization and achieved complete biochemical cure suggesting false-negative AVS result even though clinical cure was not achieved. Altogether, this means errors in 18% and 3% of lateralization diagnostics with the 11C-MTO-PET and AVS methods, respectively, among those eligible for adrenal surgery. In comparison, based on analysis of more than non-lateralizing AVS he underwent adrenalectomy based on 11C-MTO-PET lateralization and presented with complete biochemical cure but absent clinical cure. Detailed data for those who underwent AVS-guided adrenalectomy but showed discordant 11C-MTO-PET lateralization are shown in Table 2. All these subjects had lateralization index clearly above the cut point of 4 and complete biochemical cure.

### TABLE 2: Subjects operated based on AVS and with discordant 11C-MTO-PET metabolic activity side
1300 imaging studies in a recent report, anatomical imaging-based lateralization would have excluded surgical treatment from 22% of the subjects and resulted in the removal of the non-culprit adrenal gland from 6% of the subjects.\textsuperscript{13} Previous studies have shown a 36%–39% probability of errors in operation side selection based on adrenal CT, but these numbers included those diagnosed with bilateral disease.\textsuperscript{27–30}

Despite great expectations, the use of \textsuperscript{11}C-MTO-PET in the lateralization diagnostics of PA is debated. The present finding that \textsuperscript{11}C-MTO-PET does not substitute for AVS in discordant cases with unilateral PA is in line with our prospective study,\textsuperscript{28} but disagrees with two others with more favourable conclusions\textsuperscript{17,18} that applied different patient selections and methodology. Indeed, our series also included 14 subjects who were operated based on \textsuperscript{11}C-MTO-PET and presented with similar outcomes as the other subjects. Burton et al.\textsuperscript{17} performed PET studies on selected patients based on anatomical findings, and the study by O’Shea et al.\textsuperscript{18} presented a retrospective case series with only one patient undergoing both AVS and \textsuperscript{11}C-MTO-PET preoperatively. In a recent prospective study with 20 out of 25 subjects undergoing adrenalectomy, \textsuperscript{11}C-MTO-PET performed comparably to AVS and even identified unilateral PA cases missed by AVS.\textsuperscript{31} Besides the small number of subjects included, it must be noted that up to 76% of the study subjects presented with a unilateral adenoma in CT and 90% of adrenalectomized patients showed classic unilateral PA in histopathology. This suggests that \textsuperscript{11}C-MTO-PET is indeed useful in case of severe Conn’s adenoma and agrees with previous findings by Burton et al.\textsuperscript{17} who aimed to recruit patients with a unilateral aldosteronoma. However, the ability of \textsuperscript{11}C-MTO-PET to diagnose unilateral non-classic forms of PA that are becoming more prevalent remains unanswered by these studies. Altogether, differences in patient selection may partly explain the discrepancies between our results and those by Puar et al.\textsuperscript{31}

A limitation of the current study is that contrary to the protocol developed by Burton et al.,\textsuperscript{17} our PET protocol did not include pretreatment with dexamethasone. Therefore, background CYP11B1 activity, that is tracer uptake by cortisol synthase, may decrease the SUV differences in the PET scan. Although CYP11B1 activity is suppressed by dexamethasone pretreatment, the effect of dexamethasone on CYP11B2 activity, \textsuperscript{11}C-MTO uptake, and lateralization of aldosterone secretion through inhibition of ACTH secretion remains unknown. However, more than 50% suppression of plasma aldosterone concentration has been demonstrated after dexamethasone pretreatment in both APA and bilateral hyperplasia.\textsuperscript{21,32,33} The main problem with the \textsuperscript{11}C-MTO isotope tracer is its selectivity for both CYP11B1 and CYP11B2, which is an obstacle for non-invasive subtype diagnostics in PA, and more specific tracers are awaited.\textsuperscript{34}

The strength of the current approach is ascertainment of the diagnosis by including only those undergoing surgical treatment and by using immunohistochemistry in addition to assessing postoperative cure. However, further studies are needed to address the best method to exclude false positive lateralization in medically treated bilateral aldosteronism. Also, false-negative lateralization leading to inadvertent medical treatment and lack of adrenalectomy cannot be evaluated in this setting. The size of the study population and retrospective approach are limitations of our study. In addition, the postoperative evaluation time point deviated from the 6-month time defined in the PASO criteria\textsuperscript{25} in some of the subjects.

In summary, our real-world results suggest that AVS and \textsuperscript{11}C-MTO-PET-guided lateralization diagnostics lead to similar adrenalectomy outcomes but suggest caution when lateralization in AVS and \textsuperscript{11}C-MTO-PET is discordant, which poses a risk of subtype misclassification with \textsuperscript{11}C-MTO-PET.

**AUTHOR CONTRIBUTIONS**

Juha Isojärvi: Formal analysis (lead); writing – original draft (equal).
Marianna Vuukari: Data curation (lead); formal analysis (supporting); writing – original draft (equal); writing – review and editing (equal).
Ilkka Pörsti: Conceptualization (supporting); writing – review and editing (equal). Helena Leijon: Data curation (equal); methodology (equal); writing – review and editing (equal). Tiina Vesterinen: Data curation (equal); methodology (equal); writing – review and editing (equal). Marko Seppänen: Methodology (equal); writing – review and editing (equal). Pasi I Nevalainen: Conceptualization (supporting); writing – review and editing (equal). Niina Matikainen: Conceptualization (lead); funding acquisition (lead); methodology (lead); project administration (equal); writing – review and editing (lead).

**ACKNOWLEDGEMENTS**

We thank Eija Heliö for excellent technical assistance and acknowledge Helsinki Biobank (Helsinki, Finland), Auria Biobank (Turku, Finland), and Finnish Clinical Biobank Tampere (Tampere, Finland), as the origins of patient material.

**FUNDING INFORMATION**

This work was supported by a research grant from Helsinki University Hospital (VTR TYH2018111 and TYH2020402) to N.M.

**CONFLICT OF INTEREST**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**DATA AVAILABILITY STATEMENT**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

**ETHICAL APPROVAL**

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of University Helsinki (7.11.2018/ HUS/1352/2018.)

**ORCID**

Niina Matikainen https://orcid.org/0000-0003-0041-1240
REFERENCES

1. Brown JM, Siddiqui M, Calhoun DA, et al. The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern Med. 2020;173:10-20. doi:10.7326/M20-0065

2. Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008;371:1921-1926. doi:10.1016/S0140-6736(08)60834-X

3. Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient’s cohorts and in population-based studies—a review of the current literature. Horm Metab Res. 2012;44:157-162. doi:10.1055/s-0031-1295438

4. Monticone S, Burrello J, Tizzani D, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69:1811-1820. doi:10.1016/j.jacc.2017.01.052

5. Monticone S, D’Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6:41-50. doi:10.1016/S2213-8587(17)30319-4

6. Hundemer GL. Primary aldosteronism: cardiovascular outcomes pre- and post-treatment. Curr Cardiol Rep. 2019;21:93. doi:10.1007/s11886-019-1185-x

7. Hundemer GL, Curhan GC, Youzam N, Wang M, Vaidya A. Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension. 2018;72:658-666. doi:10.1161/HYPERTENSIONAHA.118.11568

8. Hundemer GL, Curhan GC, Youzam N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6:51-59. doi:10.1016/S2213-8587(17)30367-4

9. Wu VC, Wang SM, Huang KH, et al. Long-term mortality and cardiovascular events in patients with unilateral primary aldosteronism after targeted treatments. Eur J Endocrinol. 2021;186:195-205. doi:10.1530/EJE-21-0836

10. Jing Y, Liao K, Li R, et al. Cardiovascular events and all-cause mortality in surgically or medically treated primary aldosteronism: a meta-analysis. J Renin Angiotens Aldosterone Syst. 2021;22:147032032110037. doi:10.1177/14703203211003781

11. Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019;285:126-148. doi:10.1111/joim.12831

12. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889-1916. doi:10.1210/jc.2015-4061

13. Rossi GP, Crimi F, Rositto G, et al. Identification of surgically curable primary aldosteronism by imaging in a large, multiethnic international study. J Clin Endocrinol Metab. 2021;106:e4340-e4349. doi:10.1210/clinem/dgaa482

14. Rossi GP, Crimi F, Rositto G, et al. Feasibility of imaging-guided adrenalectomy in Young patients with primary aldosteronism. Hypertension. 2022;79:187-195. doi:10.1161/HYPERTENSIONAHA.121.18284

15. Rossi GP. Update in adenalin venous sampling for primary aldosteronism. Curr Opin Endocrinol Diabetes Obes. 2018;25:160-171. doi:10.1097/MED.0000000000000407

16. Rossi GP, Barisa M, Allolbio B, et al. The adrenal vein sampling international study (AVIS) for identifying the major subtypes of primary aldosteronism. J Clin Endocrinol Metab. 2012;97:1606-1614. doi:10.1210/jc.2011-2830

17. Burton TJ, Mackenzie IS, Balan K, et al. Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn’s adenomas. J Clin Endocrinol Metab. 2012;97:100-109. doi:10.1210/jc.2011-1537

18. O’Shea PM, O’Donoghue D, Bashari W, et al. (11)C-Metomidate PET/CT is a useful adjunct for lateralization of primary aldosteronism in routine clinical practice. Clin Endocrinol (Oxf). 2019;90:670-679. doi:10.1111/cen.13942

19. Chen Cardenas SM, Santhanam P. (11)C-metomidate PET in the diagnosis of adrenal masses and primary aldosteronism: a review of the literature. Endocrine. 2020;70:479-487. doi:10.1007/s12020-020-02474-3

20. Soino M, Luukkanen AK, Seppanen M, et al. Functional imaging with 11C-metomidate PET for subtype diagnosis in primary aldosteronism. Eur J Endocrinol. 2020;183:539-550. doi:10.1530/EJE-20-0532

21. Soino M, Luukkanen AK, Seppanen M, et al. Response to letter on use of functional imaging by 11C-metomidate PET for primary aldosteronism subtyping. Eur J Endocrinol. 2021;184:L11-L12. doi:10.1530/EJE-21-0048

22. Gomez-Sanchez CE, Qi X, Velarde-Miranda C, et al. Development of monoclonal antibodies against human CYP11B1 and CYP11B2. Mol Cell Endocrinol. 2014;383:111-117. doi:10.1016/j.mce.2013.11.022

23. Nakamura Y, Maeka T, Felizola SJ, et al. Adrenal CYP11B1/2 expression in primary aldosteronism: immunohistochemical analysis using novel monoclonal antibodies. Mol Cell Endocrinol. 2014;392:73-79. doi:10.1016/j.mce.2014.05.002

24. Yamazaki Y, Nakamura Y, Omata K, et al. Histopathological classification of cross-sectional image-negative hyperaldosteronism. J Clin Endocrinol Metab. 2017;102:1182-1192. doi:10.1210/jc.2016-2986

25. Williams TA, Lenders JW, Mulatero P, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017;5:689-699. doi:10.1016/S2213-8587(17)30136-3

26. Meyer LS, Wang X, Susnik E, et al. Immunohistoopathology and steroid profiles associated with biochemical outcomes after adrenalectomy for unilateral primary aldosteronism. Hypertension. 2018;72:650-657. doi:10.1161/HYPERTENSIONAHA.118.114465

27. Kemmers MJ, Lenders JW, van Outheusden L, et al. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med. 2009;151:329-337. doi:10.7326/0003-4819-151-5-200909010-00007

28. Rossi GP, Rossitto G, Amar L, et al. Clinical outcomes of 1625 patients with primary aldosteronism subtyped with adrenal vein sampling. Hypertension. 2019;74:800-808. doi:10.1161/HYPERTENSIONAHA.119.13463

29. Sarlon-Bartoli G, Michel N, Taieb D, et al. Adrenal venous sampling is crucial before an adrenalectomy whatever the adrenal-node size on computed tomography. J Hypertens. 2011;29:1196-1202. doi:10.1097/HJH.0b013e32834666af

30. Williams TA, Burrello J, Secchi LA, et al. Computed tomography and adrenal venous sampling in the diagnosis of unilateral primary aldosteronism. Hypertension. 2018;72:641-649. doi:10.1161/HYPERTENSIONAHA.118.11382

31. Puur TH, Khoob CM, Tan CJ, et al. For the PA CURE investigators. 11C-Metomidate PET-CT versus adrenal vein sampling to subtype primary aldosteronism: a prospective clinical trial. J Hypertens. 2022;40:1179-1189. doi:10.1097/HJH.000000000000313229

32. St-Jean M, Bourdeau I, Martin M, Lacroix A. Aldosterone is aberrantly regulated by various stimuli in a high proportion of patients with primary aldosteronism. J Clin Endocrinol Metab. 2021;106:e45-e60. doi:10.1210/clinem/dgaa703
33. Tezuka Y, Ishii K, Zhao L, et al. ACTH stimulation maximizes the accuracy of peripheral steroid profiling in primary aldosteronism subtyping. J Clin Endocrinol Metab. 2021;106:e3969-e3978. doi:10.1210/clinem/dgab420

34. Wannachalee T, Lieberman L, Turcu AF. High prevalence of autonomous aldosterone production in hypertension: how to identify and treat it. Curr Hypertens Rep. 2022;24:123-132. doi:10.1007/s11906-022-01176-7

How to cite this article: Isojärvi J, Viukari M, Pörsti I, et al. Lateralization in ¹¹C-Metomidate PET and outcome of adrenalectomy in primary aldosteronism. Endocrinol Diab Metab. 2022;5:e368. doi: 10.1002/edm2.368